- Home
- TNGX vs CADL Comparison
TNGX vs CADL Comparison
Compare TNGX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CADL
- Stock Information
- Founded
- TNGX 2014
- CADL 1999
- Country
- TNGX United States
- CADL United States
- Employees
- TNGX N/A
- CADL N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- CADL Health Care
- Exchange
- TNGX Nasdaq
- CADL Nasdaq
- Market Cap
- TNGX 351.2M
- CADL 252.0M
- IPO Year
- TNGX N/A
- CADL 2021
- Fundamental
- Price
- TNGX $5.87
- CADL $5.50
- Analyst Decision
- TNGX Strong Buy
- CADL Strong Buy
- Analyst Count
- TNGX 6
- CADL 5
- Target Price
- TNGX $12.20
- CADL $21.40
- AVG Volume (30 Days)
- TNGX 2.9M
- CADL 866.1K
- Earning Date
- TNGX 08-06-2025
- CADL 08-12-2025
- Dividend Yield
- TNGX N/A
- CADL N/A
- EPS Growth
- TNGX N/A
- CADL N/A
- EPS
- TNGX N/A
- CADL N/A
- Revenue
- TNGX $40,990,000.00
- CADL N/A
- Revenue This Year
- TNGX N/A
- CADL N/A
- Revenue Next Year
- TNGX N/A
- CADL N/A
- P/E Ratio
- TNGX N/A
- CADL N/A
- Revenue Growth
- TNGX 10.09
- CADL N/A
- 52 Week Low
- TNGX $1.03
- CADL $3.79
- 52 Week High
- TNGX $12.02
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- TNGX 74.27
- CADL 57.20
- Support Level
- TNGX $5.34
- CADL $4.86
- Resistance Level
- TNGX $5.63
- CADL $5.12
- Average True Range (ATR)
- TNGX 0.50
- CADL 0.28
- MACD
- TNGX -0.04
- CADL 0.06
- Stochastic Oscillator
- TNGX 84.15
- CADL 88.26
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.